Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in patients with oral lichen planus
2021-000271-36Phase 2Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of guselkumab in oral lichen planus (OLP), sponsored by Philipps-Universität Marburg. Primary endpoint: Immunologic responder rate at week 12. Started Jun 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on 2021-000271-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000271-36.